A study evaluating an impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen

Trial Profile

A study evaluating an impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Rilpivirine (Primary) ; Emtricitabine/tenofovir; Lamivudine/abacavir; Raltegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jan 2018 New trial record
    • 13 Dec 2017 Results published in the Clinical Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top